EA202092666A1 - METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG - Google Patents
METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUGInfo
- Publication number
- EA202092666A1 EA202092666A1 EA202092666A EA202092666A EA202092666A1 EA 202092666 A1 EA202092666 A1 EA 202092666A1 EA 202092666 A EA202092666 A EA 202092666A EA 202092666 A EA202092666 A EA 202092666A EA 202092666 A1 EA202092666 A1 EA 202092666A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- cancer
- tizotumab
- cdrs
- methods
- Prior art date
Links
Abstract
Настоящее изобретение относится к антителу к PD-1, содержащему определяющие комплементарность области (CDR) пембролизумаба, в комбинации с конъюгатом антитела и лекарственного средства, который связывается с тканевым фактором (TF), содержащим монометилауристатин E и CDR тизотумаба (например, тизотумаб-ведотином), и их применению в способах лечения рака, такого как рак молочной железы и рак шейки матки. Настоящее изобретение также относится к композициям и наборам, содержащим антитело к PD-1, содержащее CDR пембролизумаба, и конъюгат антитела и лекарственного средства, который связывается с TF, содержащий монометилауристатин E и CDR тизотумаба (например, тизотумаб-ведотин), для применения в лечении рака, такого как рак молочной железы и рак шейки матки.The present invention relates to an anti-PD-1 antibody containing complementarity determining regions (CDRs) of pembrolizumab, in combination with an antibody-drug conjugate that binds to tissue factor (TF) containing monomethyluristatin E and tizotumab CDRs (e.g., tizotumab-vedotin) and their use in methods of treating cancer such as breast and cervical cancer. The present invention also provides compositions and kits comprising an anti-PD-1 antibody containing pembrolizumab CDRs and an antibody-drug conjugate that binds to TF containing monomethyluristatin E and tizotumab CDRs (e.g., tizotumab-vedotin) for use in treatment cancers such as breast cancer and cervical cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862753725P | 2018-10-31 | 2018-10-31 | |
PCT/US2019/031166 WO2019217455A1 (en) | 2018-05-07 | 2019-05-07 | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092666A1 true EA202092666A1 (en) | 2021-02-20 |
Family
ID=74855488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092666A EA202092666A1 (en) | 2018-10-31 | 2019-05-07 | METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202092666A1 (en) |
-
2019
- 2019-05-07 EA EA202092666A patent/EA202092666A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092136A1 (en) | METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG | |
EA201891428A1 (en) | COMBINATION OF ANTIBODIES TO PD-1 AND BISPECIFIC ANTIBODIES TO CD20 / CD3 FOR THE TREATMENT OF MALIGNANT TUMOR | |
MX2020008445A (en) | Methods for treating cancer with anti-pd-1 antibodies. | |
EA201891178A1 (en) | Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use | |
NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
EA201691225A1 (en) | ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | |
CR20200459A (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
MX2021010116A (en) | Anti-pd-l1 antibody and use thereof. | |
FI3218005T3 (en) | Glycan-interacting compounds and methods of use | |
EA201992573A1 (en) | TREATMENT OF HER2-POSITIVE MALIGNANT NEOPLASMS | |
MX2019013753A (en) | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations. | |
MX2020008122A (en) | Anti-pd-1 antibodies. | |
MX2021009041A (en) | Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof. | |
MX2022007790A (en) | Therapy for the treatment of cancer. | |
PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
JOP20220070A1 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
MX2021003673A (en) | Anti-human vsig4 antibodies and uses thereof. | |
MX2020011823A (en) | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate. | |
EA202090741A1 (en) | CONJUGATES OF ANTIBODY TO TISSUE FACTOR AND DRUG AND THEIR APPLICATION IN TREATMENT OF CANCER | |
MX2020009111A (en) | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate. | |
MX2023001776A (en) | Antibodies against ilt2 and use thereof. | |
EA202092666A1 (en) | METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG | |
MX2021001058A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer. | |
MX2021008760A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof. | |
EA202190734A1 (en) | METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY AGAINST VEGF AND ANTIBODY ANTIBODY AGAINST TISSUE FACTOR-DRUG |